Siga Technologies (NASDAQ:SIGA) vs. Stevanato Group (NYSE:STVN) Financial Contrast

Siga Technologies (NASDAQ:SIGA) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Siga Technologies and Stevanato Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	0	0	0	0	0.00
Stevanato Group	0	2	3	1	2.83

Profitability

This table compares Siga Technologies and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Siga Technologies	45.73%	40.52%	35.62%
Stevanato Group	11.73%	10.34%	6.21%

Institutional & Insider Ownership

55.4% of Siga Technologies shares are held by institutional investors. 2.0% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Siga Technologies has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Earnings and Valuation

This table compares Siga Technologies and Stevanato Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$138.72 million	4.52	$59.21 million	$1.13	7.75
Stevanato Group	$1.19 billion	6.73	$127.45 million	€0.54	49.19

Stevanato Group has higher revenue and earnings than Siga Technologies. Siga Technologies is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

About Siga Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.